Paper34799485
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.
Laurent C and 16 others. Am J Surg Pathol, 2022. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. Papers, record 34799485. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34799485
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Burkitt Lymphoma | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Cell Transdifferentiation | |
| Comparative Genomic Hybridization | |
| Genomics | |
| Humans | |
| Immunotherapy, Adoptive | |
| In Situ Hybridization, Fluorescence | |
| Neoplasm Recurrence, Local | |
| Phosphatidylinositol 3-Kinases | |
| Proto-Oncogene Proteins p21(ras) | |
| Transcription Factors |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42393159 | Integrated bioinformatics analysis reveals fatty acid metabolism subtypes and immune landscape in recurrent implantation failure. | Sci Rep | 2026 | https://conductscience.org/library/papers/42393159 | PubMed |
| 42382044 | Epigenetics as a mechanism of lineage extinction and relapse of B-cell lymphoma treated with CD19 CAR T-cell therapy. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42382044 | PubMed |
| 42099680 | Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group. | Hemasphere | 2026 | https://conductscience.org/library/papers/42099680 | PubMed |
| 41369864 | Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy. | J Hematop | 2025 | https://conductscience.org/library/papers/41369864 | PubMed |
| 40956459 | Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40956459 | PubMed |
| 40801926 | Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop. | Virchows Arch | 2025 | https://conductscience.org/library/papers/40801926 | PubMed |
| 40578903 | DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | https://conductscience.org/library/papers/40578903 | PubMed |
| 40148484 | Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/40148484 | PubMed |
| 39406188 | Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection. | Pathobiology | 2025 | https://conductscience.org/library/papers/39406188 | PubMed |
| 39186243 | Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy. | J Hematop | 2024 | https://conductscience.org/library/papers/39186243 | PubMed |
| 38878262 | Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy. | J Hematop | 2024 | https://conductscience.org/library/papers/38878262 | PubMed |
| 38638855 | Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications. | Front Oncol | 2024 | https://conductscience.org/library/papers/38638855 | PubMed |
| 38090582 | Broadening the horizon: potential applications of CAR-T cells beyond current indications. | Front Immunol | 2023 | https://conductscience.org/library/papers/38090582 | PubMed |
| 36990772 | Histologic transformation of follicular lymphoma: pathologists' viewpoint. | J Clin Exp Hematop | 2023 | https://conductscience.org/library/papers/36990772 | PubMed |
| 35681499 | CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. | Cells | 2022 | https://conductscience.org/library/papers/35681499 | PubMed |
| 35163421 | Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163421 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34799485
GET https://conductscience.org/api/papers/v1/34799485/authors